Why the study?
The efficacy of cerebral embolic protection devices and the optimal antithrombotic management during left atrial and transcatheter mitral valve procedures have not been fully established.
Does the use of cerebral embolic protection devices reduce the risk of periprocedural stroke in patients undergoing left atrial and transcatheter mitral valve procedures?
Does the use of cerebral embolic protection devices reduce the risk of periprocedural stroke in patients undergoing left atrial and transcatheter mitral valve procedures?
While cerebral embolic protection devices capture debris during left atrial and mitral valve procedures, their clinical efficacy in preventing periprocedural stroke requires further prospective evaluation.
Answers are grounded in this paper and cite their sources.
Heightened stroke awareness is warranted during left atrial and mitral procedures; leaves open CEPD efficacy pending prospective trials.
PURPOSE OF REVIEW: This review aims to highlight the current evidence on the use of cerebral embolic protection devices (CEPD) in left atrial and transcatheter mitral valve procedures. It also aims to summarize the antithrombotic management of patients undergoing such procedures. RECENT FINDINGS: Ischemic stroke is one of the most devastating complications of structural heart procedures. The manifestation of periprocedural stroke can range from asymptomatic and detectable only through brain imaging to major stroke with neurological deficits. CEP devices were initially developed to mitigate the risk of stroke associated with transcatheter aortic valve replacement (TAVR). However, the efficacy of such devices during different cardiac interventions is yet to be fully demonstrated, especially in left atrial appendage closure (LAAO), and mitral valve interventions. Few studies demonstrated that the risk of periprocedural strokes after LAAO and mitral valve interventions is not negligible and is highest during the periprocedural period and then falls. The majority of patients undergoing those procedures have cerebral ischemic injuries detected on diffusion-weighted magnetic resonance imaging (DW-MRI). Moreover, a reasonable number of those patients had debris embolization on the filters of the CEPD. Pharmacological therapy with antithrombotic agents before, during, or after structural heart interventions is crucial and should be tailored to each patient's risk of bleeding and ischemia. Close monitoring that includes a full neurological assessment and frequent follow-up visits with cardiac echocardiography are important. The risk of periprocedural stroke in left atrial and transcatheter mitral valve procedures is not negligible. Pharmacological therapy with antithrombotic agents before, during, or after structural heart interventions is important to mitigate the risk of stroke, especially the long-term risk. More prospective studies are needed to assess the efficacy of CEPD in such procedures.
No takes yet. Share an insight, caveat, or question.
Besir et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: